TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization
(TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or
advanced hepatocellular carcinoma (HCC).
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital of Guangzhou Medical University